Authors : M. Anto Joel Roy; S. Sudharsan; P. Mahendravarman; Dr. C. Karthick

Volume/Issue : Volume 11 - 2026, Issue 5 - May

---

Google Scholar : https://tinyurl.com/mr3vnvzj

Scribd : https://tinyurl.com/3x3jmvbc

DOI : https://doi.org/10.38124/ijisrt/26may2161

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

---

Abstract : Tuberculosis (TB) continues to be a serious problem around the globe, and India is responsible for almost 27% of the world's total number of cases of TB. A prospective and observational study conducted in this regard to determine the therapeutic outcomes of 39 PTB patients receiving treatment with DOTS regimen in the Department of TB and Chest, Government Cuddalore Medical College and Hospital (GCMCH), Chidambaram, from October 2024 to March 2025. All the patients received standard drugs for DOTS including Isoniazid, Rifampicin, Pyrazinamide, and Ethambutol during the initial intensive period, whereas Isoniazid and Rifampicin during the subsequent continuation period.

Keywords : Pulmonary Tuberculosis; DOTS Therapy; Treatment Outcomes; NTEP; Sputum Conversion; Radiological Improvement.

References :

1. Trivedi, P. R., & Khakhkhar, T. M. (2019). Treatment outcome of tuberculosis patients under directly observed treatment short-course and factors affecting the outcome in tertiary care hospital. International Journal of Basic & Clinical Pharmacology, 8(5), 981–986. https://doi.org/10.18203/2319-2003.ijbcp20191588
2. Kaur, G., Goel, N.K., Kumar, D., Janmeja, A.K., Swami, H.M., & Kalia, M. (2008). Treatment Outcomes of Patients Placed on Treatment Under Directly Observed Therapy Short-Course (DOTS). Lung India, 25(2), 75–77. DOI: 10.4103/0970-2113.44124
3. Heo, E.Y., et al. (2009). Radiographic improvement and its predictors in patients with pulmonary tuberculosis. International Journal of Infectious Diseases, 13(6), e371–e376. doi: 10.1016/j.ijid.2009.01.007
4. Lee, J.J., et al. (2008). High resolution chest CT in patients with pulmonary tuberculosis: characteristic findings before and after antituberculosis therapy. European Journal of Radiology, 67(1), 100–104.
5. Bansal, N., et al. (2024). Unveiling Silent Consequences: Impact of Pulmonary Tuberculosis on Lung Health and Functional Wellbeing after Treatment. Journal of Clinical Medicine, 13(14), 4115.
6. Mechaï, F., et al. (2019). Pulmonary tuberculosis: Radiological evolution of broncho-pulmonary lesions at the end of treatment. Rev Mal Respir, 36(1), 22–30.
7. World Health Organization. (2023). Global tuberculosis report 2023. Geneva: WHO.
8. Frieden, T. R., et al. (1995). Tuberculosis. JAMA, 273(12), 943–945.
9. Udwadia, Z. F., et al. (2012). Totally drug-resistant tuberculosis in India. PLoS ONE, 7(8), e40781.
10. Isaakidis, P., et al. (2011). Ambulatory multi-drug resistant tuberculosis treatment outcomes in a cohort of HIV-infected patients in a slum setting in Mumbai, India. BMC Public Health, 11, 241.
11. Chatterjee, P., et al. (2018). Drug-resistant tuberculosis: Is India ready for the challenge? The Lancet Infectious Diseases, 18(3), 301–302.
12. Brosch, R., et al. (2002). A new evolutionary scenario for the Mycobacterium tuberculosis complex. PNAS, 99(6), 3684–3689.
13. Brennan, P. J., & Nikaido, H. (1995). The envelope of mycobacteria. Annual Review of Biochemistry, 64, 29–63.
14. Lönnroth, K., et al. (2009). Drivers of tuberculosis epidemics: The role of risk factors and social determinants. The International Journal of Tuberculosis and Lung Disease, 13(10), 1247–1254.
15. Philips, J. A., & Ernst, J. D. (2012). Tuberculosis pathogenesis and immunity. Annual Review of Pathology, 7, 353–384.
16. Barry, C. E., et al. (2009). The spectrum of latent tuberculosis: Rethinking the biology and intervention strategies. Nature Reviews Microbiology, 7(12), 845–855.
17. Sharma, S. K., & Mohan, A. (2004). Extrapulmonary tuberculosis. Indian Journal of Medical Research, 120(4), 316–353.
18. Orme, I. M. (2014). The immune response to Mycobacterium tuberculosis. Microbes and Infection, 16(6), 413–417.
19. Flynn, J. L., & Chan, J. (2001). Immunology of tuberculosis. Annual Review of Immunology, 19, 93–129.
20. Fennelly, K. P. (2020). Particle sizes of infectious aerosols: implications for infection control. Lancet Respiratory Medicine, 8(9), 914–924.
21. Yates et al. (2016); Fox et al. (2013); Martinez et al. (2017); Andrews et al. (2014); Joshi et al. (2006); Dara et al. (2015).
22. Dheda, K., et al. (2016). Tuberculosis. Lancet, 387(10024), 1211–1226.
23. Frieden, T. R., et al. (2003). Tuberculosis. The Lancet, 362(9387), 887–899.
24. Wang, L., et al. (2014). Tuberculosis control in China: success of the DOTS strategy. The Lancet, 383(9934), 1217–1225.
25. Uplekar, M., et al. (2001). Public-private mix for TB control. Bulletin of the WHO, 79(9), 745–752.
26. Mitnick, C., et al. (2003). Comprehensive treatment of extensively drug-resistant tuberculosis. NEJM, 359(6), 563–574.
27. Sachdeva, K. S., et al. (2020). India's fight against tuberculosis: Lessons from the past and the way forward. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases, 19, 100152.
28. Khaparde, S., et al. (2015). Digital health innovations under RNTCP in India. Indian Journal of Tuberculosis, 62(4), 201–207.
29. Arinaminpathy, N., et al. (2016). The impact of private sector engagement on tuberculosis outcomes in India. BMJ Global Health, 1(1), e000021.
30. Malhotra, S., et al. (2022). Impact of COVID-19 on tuberculosis programs in India. The Lancet Respiratory Medicine, 10(1), e5.
31. Rao, R., et al. (2022). India's strategy for TB elimination under NTEP. BMJ Global Health, 7(1), e008924.